The Role of Acetylcholine Mechanisms in Affective Disorders

David S. Janowsky* and David H. Overstreet

*Research Bldg. A, CB7175
Psychiatry Department
University of North Carolina
Chapel Hill, NC 27599
phone: (919) 966-0167
fax: (919) 966-0259
djanowsky@css.unc.edu


REFERENCES

  1. Amsterdam JD, Maislin G, Skolnick B, Berwish N, Winokur A. The assessment of abnormalities in hormonal responsiveness at multiple levels of the hypothalamic-pituitary-adrenocortical axis in depressive illness. Biol Psychiatry 1989;26:265–278.
  2. Avissar S, Schreiber G. Muscarinic receptor subclassification and G-proteins: significance for lithium action in affective disorders and for the treatment of extrapyramidal side effects of neuroleptics. Biol Psychiatry 1989;26:113–130.
  3. Berger M, Riemann D, Hochli D, Spiegel R. The cholinergic rapid eye movement sleep induction test with RS-86. Arch Gen Psychiatry 1989;46:421–428.
  4. Berger M, Lund R, Bronisch T, von Zeerssen D. REM latency in neurotic and endogenous depression and the cholinergic REM induction test. Psychiatry Res 1983’ 10:113-123.
  5. Berkowitz A, Sutton L, Janowsky DS, Gillin JC. Pilocarpine, an orally active muscarinic cholinergic agonist, induces REM sleep and reduces delta sleep in normal volunteers. Psychiatry Res 1990;33:113–119.
  6. Bidzinski A, Puzynski S, Mrozek S. Choline transport in erythrocytes of healthy controls and patients with endogenous major depression. New Trends Exp Clin Psychiatry 1989;5:179–185.
  7. Camarini R, Benedito MA. Chronic imipramine treatment-induced changes in acetylcholinesterase (EC 3.1.1.7) activity in discrete rat brain regions. Braz J Med Biol Res 1997; 30(8):955-960.
  8. Carroll BJ, Frazer A, Schless A, Mendels J. Cholinergic reversal of manic symptoms. Lancet 1973; 428.
  9. Casey DE. Mood Alterations during deanol therapy. Psychopharmacology (Berlin) 1979; 62:187-191.
  10. Charles HC, Lazeyras F, Krishnan KRR, Boyko OB, Payne M, Moore D. Brain choline in depression: in vivo detection of potential pharmacodynamic effects of antidepressant therapy using hydrogen localized spectroscopy. Prog Neuro-Psychopharmacol Biol Psychiatry 1993;18:1121-1127.
  11. Clarke PBS, Fu DS, Jakubovic A, Fibiger HC. Evidence that mesolimbic dopaminergic activation underlies the locomotor stimulant action of nicotine in rats. J Pharmacol Exp Ther 1988;246:701–708.
  12. Coid B, Strang M. Mania secondary to procyclidine ("Kemadrin") abuse. Br J Psychiatry 1982; 141:81-84.
  13. Cooney JM, Lucey JV, O’Keane V, Dinan TG. Specificity of the pyridostigmine/growth hormone challenge in the diagnosis of depression. Biol Psychiatry 1997; 42(9):827-833.
  14. Crespi D, Gobbi M, Mennini T. 5-HT3 serotonin hetero-receptors inhibit [3H] acethycholine release in rat cortical synaptosomes. Pharmacol Res 1997; 35(4):351-354.
  15. Dahl Re, Ryan ND, Perel J, Birmaher B, alShabbout M, Nelson B, Puig-Antich J. Cholinergic REM induction test with arecoline in depressed children. Psychiatry Res 1994; 51(3):269-282.
  16. Davis BM, Davis KL. Cholinergic mechanisms and anterior pituitary hormone secretion. Biol Psychiatry 1980; 15:303-310.
  17. Davis KL, .Berger PA, Hollister LE, DeFraites E. Physostigmine in man. Arch Gen Psychiatry; 19979; 35:119-122.
  18. Davis KL, Hollister LE, Berger PA. Choline chloride in schizophrenia. Am J Psychiatry 1979’ 136:1581-1584.
  19. Day JC, Koehl M, Deroche V, Le Moal M, Maccari S. Prenatal stress enhances stress- and corticotropin-releasing factor-induced stimulation of hippocampal acetylcoline release in adult rats. J Neurosci 1998a; 18(5):1886-1892.
  20. Dilsaver SC, Greden JF. Antidepessant withdrawal pheomena. J Clin Psychopharm 1984; 19(2):237-256.
  21. Dinan TG, O’Keane V, Thkore J. Pyridostigmine induced growth hormone release in mania: focus on the cholinergic/somatostatin system. Clin Endocrinol (Oxf) 1994; 40(1):93-96.
  22. Dinan TG. Psychoneuroendocrinology of depression. Growth hormone. Psychiatr Clin North Am 1998; 21(2):325-339.
  23. Doerr P, Berger M. Physostigmine-induced escape from dexamethasone suppression in normal adults. Biol Psychiatry 1983;18:261–268.
  24. Downs NS, Britton KT, Gibbs DM, Koob GF, Swerdlow NR. Supersensitive endocrine response to physostigmine in dopamine-depleted rats: a model of depression? Biol Psychiatry 1986; 21(8-9):775-786.
  25. Dube S, Kuman N, Ettedgui A, Pohl R, Jones D, Sitaram N. Cholinergic REM induction response: separation of anxiety and depression. Biol Psychiatry 1985;20:408–418.
  26. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry 1997; 54(7):597-606.
  27. Edelstein P, Schulz JF, Hirschowitz J, Kanter DR, Garver DL. Physostigmine and lithium response in schizophrenia. Am J Psychiatry 1981; 138:1078-1081.
  28. El-Yousef M, Janowsky DS, Davis JM, Rosenblatt JE. Induction of severe depression in marijuana intoxicated individuals. Br J Addict 1973;68:321–325.
  29. Fibiger HD, Lynch GS, Cooper HP. A biphasic action of central cholinergic stimulation on behavioral arousal in the rat. Psychopharmacologia 1971; 20:336—382.
  30. Fritze J, Lanczik M, Sofic E, Struc M, Riederer P. Cholinergic neurotransmission seems not to be involved in depression but possibly in personality. J Psychiatry Neurosci 1995; 20(1):39-48.
  31. Fritze J. The adrenergic-cholinergic imbalance hypothesis of depression: a review and a perspective. Rev Neurosci 1993; 4(1):63-93.
  32. Fujii T, Yoshizawa M, Nakai K, Fujimoto K, Suzuki T, Kawashima K. Demonstration of the facilitatory role of 8-OH-DPAT on cholinergic transmission in the rat hippocampus using in vivo microdialysis. Brain Res 1997; 761(2):244-249.
  33. Gann H, Riemann D, Hohagen F, Dressing H, Muller WE, Berger M. The sleep structure of patients with anxiety disorders in comparison to that of healthy controls and depressive patients under baseline conditions and after cholinergic stimulation. J Affect Dis 1992; 26:179–190.
  34. Gershon S, Shaw FH. Psychiatric sequelae of chronic exposure to organophosphorous insecticides. Lancet 1961; 1:1371-1374.
  35. Gilad GM. The stress-induced response of the septo-hippocampal cholinergic system. A vectorial outcome of psychoneuroendocrinological interactions. Psychoneuroendocrinology. 1987; 12(3)167-184.
  36. Gillin JC, Lauriello J, Kelsoe JR, Rapaport M, Golshan S, Kenny WM, Sutton L. No antidepressant effect of biperiden compared with placebo in depression: a double-blind 6-week clinical trial. Psychiatry Res 1995; 58(2):99-105.
  37. Gillin JC, Sutton L, Ruiz C, Kelsoe J, Dupont RM, Darko D, Risch SC, Golshan S, Janowsky D. The cholinergic rapid eye movement induction test with arecoline in depression. Arch Gen Psychiatry 1991;48:264–270.
  38. Glassman AH. Cigarette smoking: implications for psychiatric illness. Am J Psychiatry 1993;150:546–553.
  39. Hankura H, Kato T, Murashita J, Kato N. Quantitative proton magnetic resonance spectroscopy of the basal ganglion in patients with affective disorder. Eur Arch Psychiatry Clin Neuroscience 1998; 248(1):53-58.
  40. Hasey G, Hanin I. The cholinergic-adrenergic hypothesis of depression reexamined using clonidine, metoprolol, and physostigmine in an animal model. Biol Psychiatry 1991;29:127–138.
  41. Ikarashi Y, Takahashi A, Ishimaru H, Arai T, Maruyama Y. Suppression of cholinergic activity via the dopamine D2 receptor in the rat striatum. Neurochem Int 1997; 30(2):191-197.
  42. Iwamoto ET. Antinociception after nicotine administration into the mesopontine tegmentum of rats: evidence for muscarinic actions. J Pharmacol Exp Ther 1989;251:412–421.
  43. Janowsky DS, El-Yousef MK, Davis JM, Sekerke HJ. A cholinergic-adrenergic hypothesis of mania and depression. Lancet 1972; 2:632–635.
  44. Janowsky DS, El-Yousef MK, Davis JM, Sekerke HJ. Parasympathetic suppression of manic symptoms by physostigmine. Arch Gen Psychiatry 1973;28:542–547.
  45. Janowsky DS, El-Yousef MK, Davis JM. Acetylcholine and depression. Psychosom Med 1974;36:248–257.
  46. Janowsky DS, El-Yousef MK, Davis JM. Antagonistic effects of physostigmine and methylphenidate in man. Am J Psychiatry 1973;130:1370–1376.
  47. Janowsky DS, Golden RN, Risch SC. Cholinergic mechanisms in mood: Neuroendocrine aspects. Current Topics in Neuroendocrinology, Vol 8, Springere-Verlag Berlin Heidelberg 1988.
  48. Janowsky DS, Risch SC, Huey LY, Kennedy B, Ziegler M. Effects of physostigmine on pulse, blood pressure and serum epinephrine levels. Am J Psychiatry 1985;142:738–740.
  49. Janowsky DS, Risch SC, Judd LL, Huey LY, Parker DC. Brain cholinergic systems and the pathogenesis of affective disorders. In: Singh MM, Warburton DM, Lal H, eds. Central cholinergic mechanisms and adaptive dysfunction. New York: Plenum; 1985: 309–353.
  50. Janowsky DS, Risch SC, Judd LL, Huey LY, Parker DC. Cholinergic supersensitivity in affect disorder patients: behavioral and neuroendocrine observations. Psychopharmacol Bull 1981;17:129–132.
  51. Janowsky DS, Risch SC, Kennedy B, Ziegler M, Huey LY. Central muscarinic effects of physostigmine on mood, cardiovascular function, pituitary, and adrenal neuroendocrine release. Psychopharmacology 1986;89:150–154.
  52. Janowsky DS, Risch SC, Parker D, Huey LY, Judd LL. Increased vulnerability to cholinergic stimulation in affect disorder patients. Psychopharmacol Bull 1980;16:29–31.
  53. Janowsky DS, Risch SC, Ziegler M, Kennedy B, Huey L. Cholinomimetic model of motion sickness and space adaptation syndrome. Aviat Space Eng 1984;55:692-696.
  54. Janowsky DS, Risch SC. Cholinomimetic and anticholinergic drugs used to investigate an acetylcholine hypothesis of affective disorder and stress. Drug Dev Res 1984;4:125–142.
  55. Janowsky DS, Risch SC. Role of acetylcholine mechanisms in the affective disorders. In: Meltzer HY, ed. Psychopharmacology. The third generation of progress. New York: Raven Press; 1987:527–534.
  56. Jellnec T, Gardos G, Cole J. Adverse effects of antiparkinsonian drug withdrawal. Am J Psychiatry 1981; 138(12):1567-1571.
  57. Kasper S, Moises HW, Beckman H. the anticholinergic biperiden in depressive disorders. Pharmacopsychiatry 1981; 14:195
  58. Kelsoe JJr, Gillin J, Janowsky DS, Brown J, Risch SC, Lumkin B. Failure to confirm muscarinic receptors on skin fibroblasts. N Engl J Med 1985;312:861–862.
  59. Kendler K, Nenale MC, MacLean CL, Heath AC, Eaves LJ, Kessler RC. Smoking and major depression: a causal analysis. Arch Gen Psychiatry 1993;50:36–43.
  60. Kubo T. Cholinergic mechanism and blood pressure regulation in the central nervous system [In Process Citation]. Brain Res Bull 1998; 46(6):475-481.
  61. Lauriello J, Kenny WM, Sutton L, Golshan S, Ruiz C, Kelsoe J, Rappaport M, Gillin JC. The cholinergic REM sleep induction test with pilocarpine in mildly depressed patients and normal controls. Biol Psychiatry 1993;33:33–39.
  62. Leiva DB. The neurochemistry of mania: a hypothesis of etiology and rationale for treatment. Prog Neuropsychopharmacol Biol Psychiatry 1990; 14(3):423-429.
  63. Lesch KP, Manji HK. Signal-transducing G proteins and antidepressant drugs: evidence for modulation of alpha subunit gene expression in rat brain. Biol Psychiatry 1992;32:549–579.
  64. Lucey JV, Butcher G, Clare AW, Dinan TG. Elevated growth hormone responses to pyridostigmine in obsessive-compulsive disorder: evidence of cholinergic supersensitivity. Am J Psychiatry 1993;150:961–962.
  65. Mark GP, Rada PV, Shorts TJ. Inescapable stress enhances extracellular acetylcholine in the rat hippocampus and prefrontal cortex but not the nucleus accumbens or amygdala. Neuroscience 1996; 74(3):767-774.
  66. Martin JR, Driscoll P, Gentsch C. Differential response to cholinergic stimulation in psychogenetically selected rat lines. Psychopharmacology 1984;83:262–267.
  67. Martin JB, Durand D, Gurd W, Gaille G, Audet J, Brazeau P. Neuropharmacologic regulation of eipisodic growth hormone and prolactin secretion in the rat. Endocrinology 1981; 102:106-113.
  68. McCracken JT, Poland RE, Lutchmansingh P, Edwards C. Sleep electroencephalographic abnormalities in adolescent depressives: effects of scopolamine. Biol Psychiatry 1997; 42(7):577-584.
  69. McKinney WT. Animal models of depression: An overview. Psychiatr Dev 1984;2:77–96.
  70. Meltzer HY, ed. Psychopharmacology. The third generation of progress. New York: Raven Press; 1987.
  71. Mendelson WB, Lantigua RA, Wyatt RJ, Gillin JC, Jacobs LS. Piperidine enhances sleep-related and insulin induced growth hormone secretion: further evidence for a cholinergic secretory mechanism. J Clin Encocrinol Metab 1981; 52(3):409-415.
  72. Meyerson LR, Wennogle LP, Abel MS. Human brain receptor alterations in suicide victims. Pharmacol Biochem Behav 1982; 17:159-163.
  73. Modestin JJ, Hunger J, Schwartz RB. Uber die depressogene wirkung von physostigmine. Arch Psychiatrie Nervenkr 1973a; 218:67-77.
  74. Modestin JJ, Schwartz RB, Hunger J. Zur frage der beeinflussung schizophrener symptom physostigmine. Pharmacopsychiatria 1973b; 3:300-304
  75. Mohs R, Hollander E, Haroutunian V, Davidson M, Horvath T, Davis KL. Cholinomimetics in Alzheimer’s Disease. Int J Neurosci 1987; 32:775-776.
  76. Mizuno T, Kimura F. Attenuated stress response of hippocampal acetylcholine release and adrenocortical secretion in aged rats. Neurosci Lett 1997; 222(1):49-52.
  77. Nadi NS, Nurnberger JL Jr, Gershon ES. Muscarinic cholinergic receptors on skin fibroblasts in familial affective disorder. N Engl J Med 1984; 311:225-230.
  78. Nurnberger JL, Berrettini W, Mendelson WB, Sack B, Gershon ES. Measuring cholinergic sensitivity: I. Arecoline effects in bipolar patients. Biol Psychiatry 1989;25:610–617.
  79. Nurenberger JL Jr, Gershon ES, Sitaram N, Gillin JC, Brown G, Ebert M, Gold P, Jimerson D, Kessler L. Dextroamphetamine and arecoline as pharmacogenetic probes in normals and remitted bipolar patients. Psychopharmacol Bul 1981; 17:80-82.
  80. Nurnberger JL Jr, Jimerson DC, Simmons-Alling S.Behavioral, physiological and neuroendocrine response to arecoline in normal twins and well state bipolar patients. Psychiatry Res 1983a; 9:191-200.
  81. Nurnberger JL Jr, Sitaram N, Gershon ES, Gillin JC. A twin study of cholinergic REM induction. Biol Psychiatry 1983b; 18:1161-1173.
  82. O’Keane V, Abel K, Murray RM. Growth hormone responses to pyridostigmine in schizophrenia: evidence for cholinergic dysfunction. Biol Psychiatry 1994; 36(9):582-588.
  83. O’Keane V, O’Flynn K, Lucey J, Dinan TG. Pyridostigmine-induced growth hormone responses in healthy and depressed subjects: evidence for cholinergic supersensitivity in depression. Psychol Med 1992; 22(1):55-60.
  84. Oppenheimer G, Ebstein R, Belmaker R. Effects of lithium on the physostigmine-induced behavioral syndrome and plasma cyclic GMP. J Psychiatry Res 179; 14:133-139.
  85. Ostrow D, Halaris A, Dysken M, DeMet E, Harrow M, Davis JM. State dependence of noradrenergic activity in a rapidly cycling bipolar patient. J Clin Psychiatry 1984; 45(7):306-309.
  86. Overstreet DH. The Flinders sensitive line rats: a genetic animal model of depression. Neurosci Biobehav Rev 1993;17:51–68.
  87. Poland RE, McCracken JT, Lutchmansingh P, Lesser IM, Tondo L, Edwards C, Boone KB, Lin KM. Differential response of rapid eye movement sleep to cholinergic blockade by scopolamine in currently depressed, remitted, and normal control subjects. Biol Psychiatry 1997; 41(9):929-938.
  88. Pucilowski O, Overstreet DH, Rezvani AH, Janowsky DS. Chronic mild stress-induced anhedonia: greater effect in a genetic rat model of depression. Physiol Behav 1993;54:1215–1220.
  89. Rapaport MH, Risch SC, Gillin JC, Golshan S, Janowsky D. The effects of physostigmine infusion on patients with panic disorder. Biol Psychiatry 1991;29:658–664.
  90. Raskind MA, Peskind ER, Veith RC, Risse SC, Lampe TH, Borson S, Gumbrecht G, Dorsa DM. Neuroendocrine response to physostigmine in Alzheimer's Disease. Arch Gen Psychiatry 1989;46:535–540.
  91. Renshaw PF, Lafer B, Babb SM, Fava M, Stoll AL, Christensen JD Moore, CM, Yurgelun-Todd DA, Bonello CM, Pillay SS, Rothschild AJ, Nierenberg AA, Rosenbaum JF, Cohen BM. Basal ganglia choline levels in depression and response to fluoxetine treatment: An in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry 1997; 41(8):837-843.
  92. Riemann D, Gann H, Fleckenstein R, Hohagen F, Olbrich R, Berger M. Effect of RS86 on REM latency in schizophrenia. Psychiatry Res 1991;38:84–92.
  93. Riemann D, Hohagen F, Bahro M, Lis S, Stadmuller G, Gann H, Berger M. Cholinergic neurotransmission, REM sleep and depression. J Psychosom Res 1994; 38(1):15-25.
  94. Riemann D, Hohagen F, Krieger S, Gann H, Muller WE, Olbrich R, Wark HJ, Bohus M, Low H, Berger M. Cholinergic REM induction test: muscarinic supersensitivity underlies polysomnographic findings in both depression and schizophrenia. J Psychiatr Res 1994; 28(3):195-210.
  95. Risch SC, Cohen PM, Janowsky DS, Kalin NH, Insel TR, Murphy DL. Physostigmine induction of depressive symptomatology in normal human subjects. Psychiatry Res 1981;4:89–94.
  96. Risch SC, Janowsky DS, Gillin JC. Muscarinic supersensitivity of anterior pituitary ACTH and beta endorphin release in major depressive illness. Peptides 1981b; 9:789-792.
  97. Risch SC, Janowsky DS, Kalin NH, Cohen RM, Aloi JA, Murphy DL. Cholinergic beta endorphin hypersensitivity associated with depression. In: Hanin I, Usdin E, eds. Biological markers in psychiatry and neurology. Oxford: Pergamon Press; 1982:269–278.
  98. Risch SC, Kalin NH, Janowsky DS. Cholinergic challenge in affective illness: behavioral and neuroendocrine correlates. J Clin Psychopharmacol 1981;1:186–192.
  99. Risch SC, Siever LJ, Gillin JC. Differential mood effects of arecoline in depressed patients and normal volunteers. Psychopharmacol Bull 1983;19:696–698.
  100. Rowntree DW, Neven S, Wilson A. The effect of diispropylfluorophosphonate in schizophrenia and manic depressive psychosis. J Neurol Neurosurg Psychiatry 1950; 13:47-62.
  101. Rubin RT, Sekula LK, O’Toole SM, Czambiel, RK. Sexual dismorphism of human pituitary-adrenal responses to physostigmine and AVP. Biol Psychiatry 1998;43:889/
  102. Schittecatte M, Charles G, Machowsky R, Garcia J, Medlewicz J, Wilmotte J. Reduced clonidine rapid eye movement suppression in patients with primary major affective illness. Arch Gen Psychiatry 1992;49:637–642.
  103. Schreiber W, Lauer CJ, Krumrey K, Holsboer F, Krieg JC. Cholinergic REM sleep induction test in subjects at high risk for psychiatric disorders. Biol Psychiatry 1992;32:79–90.
  104. Shopsin B, Janowsky DS, Davis JM, Gershon S. Rebound phenomena in manic patients following physostigmine. Neuropsychobiology 1975; 1:180-187.
  105. Siever LJ, Risch SC, Murphy DL. Central cholinergic-adrenergic balance in the regulation of affective state. Psychiatry Res 1981; 5:108–109.
  106. Sitaram N, Jones D, Dube S, Bell J, Rivard P. Supersensitive ACh REM-induction as a genetic vulnerability marker. Int J Neurosci 1985;32:777–778.
  107. Sitaram N, Jones D, Dube S. The association of supersensitive cholinergic REM-induction and affective illness within pedigrees. J Psychiatr Res 1987;21:487–497.
  108. Sitaram N, Nurnberger J, Gershon ES, Gillin JC. Cholinergic regulation of mood and REM sleep. A potential model and marker for vulnerability to depression. Am J Psychiatry 1982;139:571–576.
  109. Sokolski KA, DeMet EM. Increased pupillary sensivity to pilocarpine in depression. Prog Neuropsychopharmacol Biol Psychiatry 1996;20:253-262.
  110. Sombonnthum P, Matsuda T, Asano S, Sakaue M, Baba A. MKC-242, a novel 5-HT1A receptor agonist, facilitates cortical acetylcholine release by a mechanism different from that of 8-OH-DPAT in awake rats. Neuropharmacology 1997; 36(11-12):1733-1739.
  111. Saito H, Matsumoto M, Togashi H, Yoshioka M. Functional interaction between serotonin and other neuronal systems: focus on in vivo microdialysis studies. Jpn J Pharmacol 1996; 70(3):203-205.
  112. Smith JA. Abuse of antiparkinsonian drugs: A review of the literature. J Clin Psychiatry 1980;41:35-354.
  113. Steinberg BJ, Trestman R, Mitropoulou V, Serby M, Silverman J, Coccaro E, Weston S, deVegvar M, Siever LJ. Depressive response to physostigmine challenge in borderline personality disorder patients. Neuropsychopharmacology 1997; 17(4):264-273.
  114. Stolerman IP, Reavill C. Primary cholinergic and indirect dopaminergic mediation of behavioural effects of nicotine. Behav Brain Res 1989;79:227–237.
  115. Stoll A, Cohen BM, Hanin I. Erythrocyte choline concentrations in psychiatric disorders. Biol Psychiatry 1991;29:309–321.
  116. Stoll AL, Sachs GS, Cohen BM, Lafer B, Christensen JD, Renshaw PF. Choline in the treatment of rapid-cycling bipolar disorder: clinical and neurochemical findings in lithium-treated patients. Biol Psychiatry 1996; 40(5):382-388.
  117. Tamminga C, Smith RC, Change S, Haraszti JS, Davis KL. Depression associated with oral choline. Lancet 1976; 2:905.
  118. Tandon R, Greden JF. Cholinergic hyperactivity and negative schizophrenic symptoms: A model of dopaminergic/cholinergic interactions in schizophrenia. Arch Gen Psychiatry 1989; 46:745-753.
  119. Tandon R, Greden JF, Haskett RF. Cholinergic hyperactivity and negative symptoms: behavioral effects of physostigmine in normal controls. Schizophr Res 1993; 9(1):19-23.
  120. Tandon R, Greden JF, Silk KR. Treatment of negative schizophrenic symptoms with trihexyphenidyl. J Clin Psychopharmacol 1988; 9:212–215.
  121. Thakkar MM, Strecker RE, McCarley RW. Behavioral state control through differential serotonergic inhibition in the mesopontine cholinergic nuclei: a simultaneous unit recording and microdialysis study. J Neurosci 1998; 18(4):5490-5497.
  122. Walker CD, Aubert ML, Meaney MJ, Driscoll P. Individual differences in the activity of the hypothalamus-pituitary-adrenocortical system after stress: use of psychogenetically selected rat lines. In: Driscoll P, ed. Genetically defined animal models of neurobehavioral dysfunctions. Boston: Birkhauser; 1992:276–296.
  123. Zhang JF, Zheng F. The role of paraventricular nucleus of hypothalamus in stress-ulcer formation in rats. Brain Res 1997; 761(2):203-209.

Back to Chapter

published 2000